RAINBOW study open to recruitment
14 May 2020
A randomised phase II/III study in Waldenströms macroglobulinaemia (WM) has opened to recruitment in the UK. The RAINBOW study is run by the CR UK & UCL Cancer Trials Centre and is supported by Janssen-Cilag Ltd.

Waldenström's macroglobulinaemia (WM) is a slow-growing type of non-Hodgkin lymphoma which affects certain white blood cells. The RAINBOW study will be assessing ‘chemotherapy free’ treatment as primary therapy for WM. Researchers are looking to find out whether this can potentially improve response outcome and durability, and, importantly, reduce toxicity for WM patients.

The study will collect information and samples from at least 148 patients over the next 4 years. Patients who take part in the trial will receive the drug ibrutinib in combination with rituximab or a combination of dexamethasone, rituximab and cyclophosphamide.

RAINBOW will be run at 50 hospitals in the UK. There is more information about the RAINBOW trial on the UCL CTC website.

Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2022 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us